InsidersTradesSigma
Transcode Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)
SEC:transcode-therapeutics-inc-e12fc8US·SEC (Form 4)Mcap 6M€Healthcare
Explore the full directors' dealings record of Transcode Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare sector, Transcode Therapeutics, Inc. has published 2 insider filings. Market capitalisation: €6m. The latest transaction was filed on 17 June 2022 (Acquisition). Among the most active insiders: Fitzgerald Thomas A. Every trade is openly available.
2
Insider Decl.
0
Thresholds
€62,566
2 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
Analyst consensus
Income statement
Net income−34.7 M€0.0% margin
Valuation
P/Book3.8x
Beta1.40
Balance sheet & cash
Market cap6.0 M€
Free Cash Flow−19.5 M€
Profitability & ownership
ROE-46.3%
ROA-14.1%
% insiders9.2%
% institutions8.6%
Last declaration on 17 June 2022
Declarations2 total
Executives▲Purchase◆Signal · 53SEC
€14,45012,000 shares@ €1.20420.24% mcap100.0% of flow
Common Stock
SEC:0001104659-22-072369:0·
Ideal exit: 13 Mar 2023 (T+270)
Executives▲Purchase◆Signal · 58SEC
€48,11628,000 shares@ €1.71840.80% mcap100.0% of flow
Common Stock
SEC:0001104659-22-067099:0·
Ideal exit: 21 Feb 2023 (T+270)
2 of 2 declarations